This study will explore the ability of patients on first line combination immunotherapy to sample cytokines at home. The data from this study will be used to evaluate the feasibility of in-home testing and the ability to analyse patients cytokine profiles retrospectively to help feed the development of further studies.

Patients will be informed of the study and given a minimum of 24 hours to consider. Once consented patients will enter the study where they will take cytokine samples at home over a 12 week period.

Inclusion Criteria:

• Voluntary informed consent.
• Aged at least 18 years.
• Diagnosis of locally advanced or metastatic RCC, Melanoma or NSCLC
• In the opinion of the investigator deemed suitable to receive first-line combination immunotherapy (RCC and MM) or combination immunotherapy and chemotherapy (NSCLC).
• Willingness to comply with scheduled trial procedures.
• Capable of performing own dry blood sampling procedure, or a carer who is willing and able to perform them.

Exclusion Criteria:

• Previous immunotherapy (including any CPI either as single agent on in combination, or high dose interleukin-2).
• Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements.
• Patients receiving long term oral anticoagulation deemed by the clinician to be at risk from daily finger pricking.

Patients receiving checkpoint inhibitor therapy as first line treatment of renal cell carcinoma, metastatic melanoma or non-small cell lung cancer (in combination with chemotherapy for NSCLC).